Cite
Empagliflozin and Dapagliflozin Reduce ROS Generation and Restore NO Bioavailability in Tumor Necrosis Factor α-Stimulated Human Coronary Arterial Endothelial Cells
MLA
Laween Uthman, et al. “Empagliflozin and Dapagliflozin Reduce ROS Generation and Restore NO Bioavailability in Tumor Necrosis Factor α-Stimulated Human Coronary Arterial Endothelial Cells.” Cellular Physiology and Biochemistry, vol. 53, no. 5, Nov. 2019, pp. 865–86. EBSCOhost, https://doi.org/10.33594/000000178.
APA
Laween Uthman, Anna Homayr, Rio P. Juni, Eva L. Spin, Raphaela Kerindongo, Marleen Boomsma, Markus W. Hollmann, Benedikt Preckel, Pieter Koolwijk, Victor W.M. van Hinsbergh, Coert J. Zuurbier, Martin Albrecht, & Nina C. Weber. (2019). Empagliflozin and Dapagliflozin Reduce ROS Generation and Restore NO Bioavailability in Tumor Necrosis Factor α-Stimulated Human Coronary Arterial Endothelial Cells. Cellular Physiology and Biochemistry, 53(5), 865–886. https://doi.org/10.33594/000000178
Chicago
Laween Uthman, Anna Homayr, Rio P. Juni, Eva L. Spin, Raphaela Kerindongo, Marleen Boomsma, Markus W. Hollmann, et al. 2019. “Empagliflozin and Dapagliflozin Reduce ROS Generation and Restore NO Bioavailability in Tumor Necrosis Factor α-Stimulated Human Coronary Arterial Endothelial Cells.” Cellular Physiology and Biochemistry 53 (5): 865–86. doi:10.33594/000000178.